Aclaris Therapeutics ACRS Single Reportable — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's single reportable — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's single reportable — operating income?
- Aclaris Therapeutics (ACRS) reported single reportable — operating income of -$22.19M in Q1 2026.
- How has Aclaris Therapeutics's single reportable — operating income changed year-over-year?
- Aclaris Therapeutics's single reportable — operating income decreased by 22.7% year-over-year, from -$18.08M to -$22.19M.
- What does single reportable — operating income mean?
- Calculated as the segment's total revenue minus its operating expenses, including research, development, and administrative costs. This metric represents the core profitability of the segment's business operations before interest and taxes. It is the primary measure of the segment's ability to generate sustainable value from its activities.